Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0117

Scientific exchange · Dr. Benedikt Fischer

09 Apr 2026 · In person · Dr. Benedikt Fischer, Guy's and St Thomas' · MSL James Whitfield · Vantrexa

ReviewedManualENG-0117—

Capture insight from this engagement

Location: Guy's and St Thomas'
Therapeutic area: Oncology
Country: United Kingdom
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

PD-L1 testing turnaround

Scientific content used

PD-L1 testing pathway infographic

Questions raised

No questions recorded.

Notes

Scientific exchange with pathologist at Guy's and St Thomas'. Discussed pd-l1 testing turnaround.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Share MI standard response

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 5
Depth of exchange: 3
Actionability: 4

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0117

Audit history (0)

All create, update and approval events for this record

No audit events in sample data